Cadila Pharmaceuticals inks agreement with Norway based Serca Pharmaceuticals for better treatment of heart patients

Ahmedabad,  January 26, 2019:  Cadila Pharmaceuticals limited, a research-based pharma group in India enters into an agreement with Norway based Inven2’s startup company, Serca Pharmaceuticals. The agreement was recently signed with Cadila
Pharmaceutical Limited. The signing took place in New Delhi in India in connection with the official state visit to Erna Solberg. The agreement is about developing a new and better treatment for patients afflicted with heart attack.

Basis the agreement Cadila Pharmaceuticals will develop a new treatment for patients afflicted with heart attack, which SERCA Pharmaceuticals can advance to global markets. The new drug is based on an invention made by Professor Kjetil Taskén and co-workers at  the University of Oslo and Oslo University Hospital.

Serca Pharmaceuticals work is based on breakthrough science from Kjetil Taskens Group at the University of Oslo (UiO). Serca is now building up the company in Norway. Serca’s drug is aiming to help patients from getting secondary damage from cardiac disease, which is
an unmet Medical need. SERCA Pharmaceuticals will develop a drug treatment for injuries that occur when treating myocardial infarction.

Inven2 is the largest contributor in Norway within the field of commercialization of research, owned by the University of Oslo and Oslo University Hospital, Norway’s largest and leading university and hospital representing pioneering research.

Corporate Comm India(CCI Newswire)